Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 8/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | ICMT | O60725 | 2/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710269 | 0.91 | SCN2A (0.35) | TRPA1F11KLKB1 | |
| SCHEMBL6708800 | 0.90 | KDM1A (0.34) | LCKICMTFYNKDM1A | |
| SCHEMBL6709898 | 0.89 | GRIK1 (0.36) | GCKLCK | |
| SCHEMBL6711732 | 0.89 | GRIK1 (0.38) | F11KLKB1 | |
| SCHEMBL6919319 | 0.87 | BRPF1 (0.35) | GCK | |
| SCHEMBL6710160 | 0.86 | TP53 (0.36) | — | |
| SCHEMBL6707654 | 0.86 | ALK (0.40) | LCKFYN | |
| SCHEMBL6707657 | 0.86 | ALK (0.40) | LCKFYN | |
| SCHEMBL6710259 | 0.86 | BRD4 (0.36) | KDM1A | |
| SCHEMBL6711764 | 0.86 | GCK (0.33) | GCKICMTTRPA1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GCK 1874/4885LCK 4247/4885ICMT 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.